Literature DB >> 11836401

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.

Renata Bures1, Lynn Morris, Carolyn Williamson, Gita Ramjee, Mark Deers, Susan A Fiscus, Salim Abdool-Karim, David C Montefiori.   

Abstract

Clade C is one of the most prevalent genetic subtypes of human immunodeficiency virus type 1 (HIV-1) in the world today and one of the least studied with respect to neutralizing antibodies. Most information on HIV-1 serology as it relates to neutralization is derived from clade B. Clade C primary isolates of HIV-1 from South Africa and Malawi were shown here to resemble clade B isolates in their resistance to inhibition by soluble CD4 and their sensitivity to neutralization by human monoclonal antibody immunoglobulin G1b12 and, to a lesser extent, 2F5. Unlike clade B isolates, however, all 16 clade C isolates examined resisted neutralization by 2G12. Infection with clade C HIV-1 in a cohort of female sex workers in South Africa generated antibodies that neutralized the autologous clade C isolate and T-cell-line-adapted (TCLA) strains of clade B. Neutralization of clade B TCLA strains was much more sensitive to the presence of autologous gp120 V3 loop peptides compared to the neutralization of clade C isolates in most cases. Thus, the native structure of gp120 on primary isolates of clade C will likely pose a challenge for neutralizing antibody induction by candidate HIV-1 vaccines much the same as it has for clade B. The autologous neutralizing antibody response following primary infection with clade C HIV-1 in South Africa matured slowly, requiring at least 4 to 5 months to become detectable. Once detectable, extensive cross-neutralization of heterologous clade C isolates from South Africa was observed, suggesting an unusual degree of shared neutralization determinants at a regional level. This high frequency of cross-neutralization differed significantly from the ability of South African clade C serum samples to neutralize clade B isolates but did not differ significantly from results of other combinations of clade B and C reagents tested in checkerboard assays. Notably, two clade C serum samples obtained after less than 2 years of infection neutralized a broad spectrum of clade B and C isolates. Other individual serum samples showed a significant clade preference in their neutralizing activity. Our results suggest that clades B and C are each comprised of multiple neutralization serotypes, some of which are more clade specific than others. The clustering of shared neutralization determinants on clade C primary HIV-1 isolates from South Africa suggests that neutralizing antibodies induced by vaccines will have less epitope diversity to overcome at a regional level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836401      PMCID: PMC135941          DOI: 10.1128/jvi.76.5.2233-2244.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

1.  Identification of HIV type 1 intersubtype recombinants in South Africa using env and gag heteroduplex mobility assays.

Authors:  H Bredell; G Hunt; B Morgan; C T Tiemessen; D J Martin; L Morris
Journal:  AIDS Res Hum Retroviruses       Date:  2000-03-20       Impact factor: 2.205

Review 2.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

Authors:  J Esparza; N Bhamarapravati
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

Review 3.  Human trials of HIV-1 vaccines.

Authors:  M J Mulligan; J Weber
Journal:  AIDS       Date:  1999       Impact factor: 4.177

Review 4.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

5.  Characterization of full-length HIV type 1 subtype C sequences from South Africa.

Authors:  J van Harmelen; C Williamson; B Kim; L Morris; J Carr; S S Karim; F McCutchan
Journal:  AIDS Res Hum Retroviruses       Date:  2001-11-01       Impact factor: 2.205

6.  Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.

Authors:  W Xu; B A Smith-Franklin; P L Li; C Wood; J He; Q Du; G J Bhat; C Kankasa; H Katinger; L A Cavacini; M R Posner; D R Burton; T C Chou; R M Ruprecht
Journal:  J Hum Virol       Date:  2001 Mar-Apr

7.  Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

Authors:  R Bures; A Gaitan; T Zhu; C Graziosi; K M McGrath; J Tartaglia; P Caudrelier; R El Habib; M Klein; A Lazzarin; D M Stablein; M Deers; L Corey; M L Greenberg; D H Schwartz; D C Montefiori
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

8.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

9.  CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis.

Authors:  L Morris; T Cilliers; H Bredell; M Phoswa; D J Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2001-05-20       Impact factor: 2.205

10.  Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India.

Authors:  D Cecilia; S S Kulkarni; S P Tripathy; R R Gangakhedkar; R S Paranjape; D A Gadkari
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

View more
  54 in total

1.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

2.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 3.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

4.  Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Authors:  Bing Li; Julie M Decker; Roy W Johnson; Frederic Bibollet-Ruche; Xiping Wei; Joseph Mulenga; Susan Allen; Eric Hunter; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 7.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

8.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

9.  Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

Authors:  Julie I Jay; Bonnie E Lai; David G Myszka; Alamelu Mahalingam; Kris Langheinrich; David F Katz; Patrick F Kiser
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

10.  Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.

Authors:  Smita Kulkarni; Srikanth Tripathy; Raman Gangakhedkar; Sushama Jadhav; Kalpana Agnihotri; Suvarna Sane; Robert Bollinger; Ramesh Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.